Blueprint Medicines Corp (NASDAQ: BPMC) is 46.72% higher on its value in year-to-date trading and has touched a low of $73.04 and a high of $128.24 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The BPMC stock was last observed hovering at around $127.97 in the last trading session, with the day’s loss setting it 0.0%.
Currently trading at $127.97, the stock is 16.30% and 31.61% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 4.14 million and changing 0.00% at the moment leaves the stock 35.22% off its SMA200. BPMC registered 22.55% gain for a year compared to 6-month gain of 34.59%. The firm has a 50-day simple moving average (SMA 50) of $97.2357 and a 200-day simple moving average (SMA200) of $94.64025.
The stock witnessed a 31.70% loss in the last 1 month and extending the period to 3 months gives it a 45.82%, and is 0.29% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 0.10% over the week and 5.71% over the month.
Blueprint Medicines Corp (BPMC) has around 649 employees, a market worth around $8.26B and $562.12M in sales. Fwd P/E is 139.32. Profit margin for the company is -27.70%. Distance from 52-week low is 75.21% and -0.21% from its 52-week high. The company has generated returns on investments over the last 12 months (-16.74%).
with sales reaching $171.34M over the same period.The EPS is expected to grow by 34.23% this year, but quarterly earnings will post 41.62% year-over-year. Quarterly sales are estimated to grow 24.01% in year-over-year returns.
Blueprint Medicines Corp (BPMC) Top Institutional Holders
490.0 institutions hold shares in Blueprint Medicines Corp (BPMC), with institutional investors hold 110.37% of the company’s shares. The shares outstanding are 64.56M, and float is at 62.21M with Short Float at 9.11%. Institutions hold 109.42% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 6.65 million shares valued at $716.45 million. The investor’s holdings represent 10.5758% of the BPMC Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 6.54 million shares valued at $704.72 million to account for 10.4026 of the shares outstanding. The other top investors are PRICE T ROWE ASSOCIATES INC /MD/ which holds 5.87 million shares representing 9.3445% and valued at over $633.03 million, while FMR LLC holds 7.6903 of the shares totaling 4.83 million with a market value of $520.97 million.
Blueprint Medicines Corp (BPMC) Insider Activity
The most recent transaction is an insider sale by Carter Percy H., the company’s CHIEF SCIENTIFIC OFFICER. SEC filings show that Carter Percy H. sold 2,659 shares of the company’s common stock on Jun 03 ’25 at a price of $127.88 per share for a total of $0.34 million. Following the sale, the insider now owns 54206.0 shares.
Blueprint Medicines Corp disclosed in a document filed with the SEC on May 27 ’25 that Albers Jeffrey W. (Director) sold a total of 5,000 shares of the company’s common stock. The trade occurred on May 27 ’25 and was made at $101.14 per share for $0.51 million. Following the transaction, the insider now directly holds 0.15 million shares of the BPMC stock.
Still, SEC filings show that on May 27 ’25, Albers Jeffrey W. (Director) Proposed Sale 5,000 shares at an average price of $101.14 for $0.51 million. The insider now directly holds shares of Blueprint Medicines Corp (BPMC).
